Recent advances include the nonsteroidal MRA finerenone and SGLT-2 inhibitors, which have demonstrated cardiovascular and renal benefits in patients with mild to moderate CKD, as well as acetazolamide, which has shown short-term efficacy as an adjunctive decongestive therapy in acute HF. Here, SLC5A2 is linked to chronic kidney disease.